Researchers published a Nature Communications report demonstrating a bioengineered viral platform that edits RNA in macrophages in vivo to treat sepsis. The chemogenetic system enables cell-type–selective RNA modulation within living organisms, offering a potential therapeutic route for overwhelming infections by reprogramming innate immune cells. The work includes preclinical efficacy data and outlines delivery and targeting strategies that could translate into first-in-human programs if safety and delivery hurdles are addressed.